STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (30,255,244)	$ (22,134,640)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	2,159,729	633,529
Share based payments for services	862,796	856,025
Equity based compensation	10,112,968	4,428,174
Common stock contributed to 401(k) plan	163,340	143,878
Shares issued for settlement of clinical research costs	1,769,500	3,400,000
Loss on derivative instruments	349,078	760,603
Warrant inducement expense	805,753	0
Modification of warrants	5,554	0
Capitalized lease interest	0	128,194
(Increase)/decrease in assets:
Receivables	7,843	55,892
Prepaid expenses	(623,608)	(137,768)
Supplies used for manufacturing	(37,689)	(137,125)
Increase/(decrease) in liabilities:
Accounts payable	(766,073)	(4,084,410)
Accrued expenses	406,083	(170,878)
Due to employees	(261,420)	(55,499)
Other liabilities	25,229	(6,660)
Net cash used in operating activities	(15,276,161)	(16,320,685)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment	(2,654,906)	(177,779)
Expenditures for patent costs	(39,975)	(158,060)
Net cash used in investing activities	(2,694,881)	(335,839)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock	13,992,439	0
Payments of stock issuance costs	(752,804)	(163,364)
Proceeds from exercise of warrants	12,072,465	14,517,260
Proceeds from exercises of options	338,328	150,482
Proceeds from the purchase of stock by officers and directors	184,990	291,997
Payments on obligations under finance leases	(800,241)	(5,121)
Net cash provided by financing activities	25,035,177	14,791,254
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	7,064,135	(1,865,270)
CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR	8,444,774	10,310,044
CASH AND CASH EQUIVALENTS, END OF YEAR	15,508,909	8,444,774
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Property and equipment purchases included in accounts payable	1,184,723	17,329
Prepaid consulting services paid with issuance of common stock	164,871	22,563
Right of use assets acquired and liabilities incurred	399,032	0
Exercise of derivative liabilities	3,071,775	3,589,357
Lease obligation included in accounts payable	790	441
Stock issuance costs included in current liabilities	50,499	15,580
Capitalizable patent costs included in current liabilities	15,000	0
Accrued consulting services to be paid with common stock	55,000	0
Cash paid for interest	$ 1,155,026	$ 1,809,242